<DOC>
	<DOC>NCT01147848</DOC>
	<brief_summary>The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily with fluticasone propionate/salmeterol administered twice daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 24-week period.</brief_summary>
	<brief_title>HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Clinical diagnosis of asthma Reversibility of at least 12% and at least 200mLs within 1040 minutes following 24 inhalations of albuterol FEV1 of 4085% predicted normal Currently using inhaled corticosteroid therapy History of lifethreatening asthma within previous 5 years (requiring intubation and/or was associated with hypercapnoea, respiratory arrest or hypoxic seizures) Respiratory infection or oral candidiasis Asthma exacerbation requiring oral corticosteroids or that resulted in overnight hospitalisation requiring additional asthma treatment Uncontrolled disease or clinical abnormality Allergies Taking another investigational medication or prohibited medication Night shift workers Current smokers or subjects with smoking history of at least 10 pack years</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Salmeterol</keyword>
	<keyword>fluticasone furoate</keyword>
	<keyword>Vilanterol</keyword>
	<keyword>fluticasone propionate</keyword>
	<keyword>GW642444</keyword>
</DOC>